Universitetssykehuset Nord-Norge HF
- Address
- lock Available on a paid plan
Universitetssykehuset Nord-Norge HF - Advanced Clinical Research Center
Universitetssykehuset Nord-Norge HF (University Hospital of North Norway) is a leading academic medical center conducting comprehensive clinical research across multiple therapeutic areas. The institution demonstrates particular expertise in pediatric oncology and hematology, with extensive involvement in collaborative Nordic and international trials for childhood cancers including acute myeloid leukemia, acute lymphoblastic leukemia, and rare conditions such as Langerhans cell histiocytosis and lymphoblastic lymphoma.
- Rheumatology and Autoimmune Disorders: Pioneering research in juvenile idiopathic arthritis, rheumatoid arthritis, polymyalgia rheumatica, systemic sclerosis, and multiple sclerosis, including innovative therapeutic drug monitoring and cellular therapy approaches
- Oncology Research: Comprehensive cancer trials spanning breast cancer, lung cancer, colorectal cancer, ovarian cancer, prostate cancer, and rare malignancies including mantle cell lymphoma and Ewing sarcoma
- Neurological and Psychiatric Disorders: Advanced studies in Alzheimer's disease, amyotrophic lateral sclerosis, dementia with Lewy bodies, chronic migraine, and substance use disorders
- Pediatric Specialties: Leading contributions to international pediatric protocols including inflammatory bowel disease, low-grade glioma, and complex treatment withdrawal strategies in juvenile arthritis
The center actively participates in precision medicine initiatives and biomarker-driven treatment selection, while also conducting practical clinical trials in areas such as obstetrics, gastroenterology (celiac disease, eosinophilic esophagitis), endocrinology (thyroid eye disease, autonomous cortisol secretion), and chronic kidney disease. The institution's research portfolio reflects a commitment to improving outcomes across the lifespan, from neonates to adults, with particular emphasis on Nordic collaborative research networks and innovative treatment paradigms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 22 therapeutic areas and 15 of 248 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 235 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 41 by active trials.
- 1Oslo University Hospital HF9active
lock +40 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF17trials
lock +24 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitetssykehuset Nord-Norge HF
lock Showing 1 of 122 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter Non-Inferiority Trial Comparing Rituximab and Ocrelizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis Aged 18-60 Years | Helse Bergen HF | Phase III | Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 248 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 8 | Unknown | 2015-05-05 | 2025-08-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.